Matches 1 - 50 out of 167 1 2 3 4 >

AcclaimIP-ad

Match Document Document Title
9040480 Synthesis of glucagon-like peptide  
A new method of synthesizing GLP-1 peptide is devised.
9034819 Method of lowering cholesterol and triglycerides by administering exendins  
Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained...
9018162 Methods for rapidly treating severe hypoglycemia  
Disclosed is a method for treating or preventing hypoglycemia in a patient comprising administering an effective amount of a composition comprising a glucagon peptide which has been dried in a...
9018164 Glucagon analogs exhibiting physiological solubility and stability  
Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon peptide has been modified by pegylation, or the addition of a carboxy terminal...
9006178 Double-acylated GLP-1 derivatives with a linker  
The invention relates to a derivative of a GLP-1 analog, which analog comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at...
8993517 Albumin fusion proteins  
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors...
8980244 Method of treating type 1 diabetes by administering NKp46 polypeptide  
The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention...
8975223 Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146  
Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia,...
8969294 Glucagon/GLP-1 receptor co-agonists  
Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular...
8969288 Amide based glucagon and superfamily peptide prodrugs  
Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an...
8969293 Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device  
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable...
8962636 Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions  
The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable...
8957021 Glucose-regulating polypeptides and methods of making and using same  
The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors...
8951965 Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes  
The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the...
8951959 Glucagon-like peptide-1 analogues and uses thereof  
Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue...
8951962 Modified exendins and exendin agonists  
Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods...
8946149 Use of exendin and analogs thereof to delay or prevent cardiac remodeling  
The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent,...
8940316 Osmotic delivery comprising an insulinotropic peptide and uses thereof  
A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase...
8937042 Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide  
Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.
RE45313 Exendin variant peptides  
The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.
8921314 Conjugates of GLP-1 agonists and uses thereof  
The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell...
8906851 Method for treating diabetes  
Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog...
8889618 C-terminal fragments of glucagon-like peptide-1 (GLP-1)  
C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP 1), and methods of use thereof, e.g., for the treatment of obesity and obesity-related disorders, e.g., diabetes and the metabolic syndrome.
8889619 Fusion protein of Exendin-4 and its analog, preparation method and use thereof  
Provided are a fusion protein of Exendin-4 and its analog, the preparation method and use thereof. The fusion protein is obtained by fusing of Exendin-4 or its analog to Fc region of human IgG2...
8877708 Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders  
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central...
8853157 Methods of treating steroid-induced obesity using GLP-1 agonists  
The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.
8853159 GLP-1 Fusion Peptides  
The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component...
8846613 Pharmaceutical combinations for the treatment of metabolic disorders  
The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment...
8815802 GLP-1 analogues and derivatives  
The invention relates to a GLP-1 analog which comprises a histidine (H) residue at a position corresponding to position 31 of GLP-1(7-37) (SEQ ID NO: 1), a glutamine (Q) residue at a position...
8809271 Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device  
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable...
8791066 Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1]  
The present invention provides polypeptides that include an O-linked glycoconjugate in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked...
8778872 Amide based glucagon superfamily peptide prodrugs  
Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an...
8772232 Protracted exendin-4 compounds  
Novel protracted exendin-4 compounds and therapeutic uses thereof.
8765669 Glycosylated GLP-1 peptide  
Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain...
8759295 Peptide-peptidase inhibitor conjugates and methods of using same  
Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders,...
8759290 Oral glucagon-like peptide conjugates for metabolic diseases  
The present invention relates to the field of metabolic compound conjugates, methods of forming said conjugates and uses of these conjugates in the treatment of diabetes and conditions related to...
8748377 Pharmaceutical compositions  
The present invention provides pharmaceutical compositions comprising at least one polypeptide having GLP-1 activity wherein an effective dose of said pharmaceutical composition comprises 15 mg,...
8748376 Stable formulations of peptides  
Stable pharmaceutical composition comprising insulinotropic peptide.
8735349 Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L  
The present invention refers to a pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
8729011 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Amide based glucagon superfamily peptide prodrugs
 
Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an...
8729017 Glucagon/GLP-1 receptor co-agonists  
Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
8729019 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents  
Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the...
8716221 Modified exendins and uses thereof  
The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity...
8710002 Methods of enhancing diabetes resolution  
Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an...
8710003 Treatment of diabetes with milk protein hydrolysate  
A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of...
8703701 Glucagon/GLP-1 receptor co-agonists  
Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon (SEQ ID NO: 2) that exhibit activity at the glucagon receptor, activity at the GLP-1...
8697647 Hybrid polypeptides with selectable properties  
The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by...
8697648 Protein agent for diabetes treatment and β cell imaging  
The 30 amino acid peptide GLP-1 has been integrated into the stable host protein human calbindin D9k. The fusion protein binds to GLP-1R. The fusion protein agents can be useful for both diabetes...
8680051 Method of ameliorating symptoms of type 1-diabetes using GABA related compounds and GLP-1/exendin-4 compounds  
A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided...
8669228 Glucagon analogs exhibiting enhanced solubility in physiological pH buffers  
Modified glucagon peptides are disclosed having improved solubility while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with,...
Matches 1 - 50 out of 167 1 2 3 4 >